Need for a Public Health Response to the Unregulated Sales of Amanita muscaria Mushrooms
Eric C. Leas, Nora Satybaldiyeva, Wayne Kepner, Kevin H. Yang, Raquel Harati, Jamie Corroon, Matthieu Rouffet
American Journal of Preventive Medicine June 10, 2024 DOI: 10.1016/j.amepre.2024.05.006 via OpenAlex
Summary
AI-generated from the abstractUse of psilocybin-containing mushrooms among U.S. adults rose from 11.4% in 2021 to 12.3% in 2022, making them the most commonly used hallucinogenic substance. This growing interest has spurred a commercial market for other mushrooms, including Amanita muscaria, which contains the psychoactive compounds muscimol and ibotenic acid.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | U.S. adults |
| Keywords | Amanita Public health Business Environmental health Medicine |
| Citations | 10 |
| Key finding | Psilocybin-containing mushroom use among U.S. adults increased significantly from 2021 to 2022, and Amanita muscaria is now part of a new commercial market for other psychoactive mushrooms. |
Abstract
Interest in psilocybin-containing mushrooms is increasing in the U.S., with 12.3% of U.S. adults reporting use of psilocybin-containing mushrooms in 2022, up significantly from 11.4% in 2021.1 This makes psilocybin-containing mushrooms the most commonly used hallucinogenic substance. This growing interest in psilocybin-containing mushrooms has also sparked a new commercial market for other types of mushrooms. Some of these mushrooms have potent pharmacological properties including Amanita muscaria mushrooms (Figure 1), which contain the compounds muscimol and its biosynthetic precursor, ibotenic acid.